''Efficacy of Propranolol in the Treatment of Infantile Hemangioma" (NCT04684667) | Clinical Trial Compass
UnknownPhase 2
''Efficacy of Propranolol in the Treatment of Infantile Hemangioma"
Egypt100 participantsStarted 2021-01-01
Plain-language summary
''Evaluation of the Efficacy of Propranolol in the Treatment of Infantile Hemangioma"
Who can participate
Age range1 Day – 1 Year
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Children diagnosed with problematic infantile hemangiomas:
A-Large hemangiomas at increased risk of scarring or disfigurement at any site. B-Hemangiomas carrying functional risks near the eyes, nose, natural orifices, limbs, genitalia.
C-Ulcerated infantile hemangiomas. D-Uncomplicated progressive infantile hemangiomas with unpredictable future course.
E-Life-threatening hemangiomas.
* Multiple hemangiomas
Exclusion Criteria:
* Patients older than 1 year of age.
* Patients with heart diseases.
* Patients with history of bronchspasm or wheezing.
* Patients with Hypotension.
* Patients with Hypertension.
* Premature infants with corrected age less than 5 weeks.
* Patients with conditions affecting blood glucose maintenance.
* Patients with liver failure.
* Patients with PHACES syndrome.
What they're measuring
1
Complete clinical clearance of hemangioma or reduction of hemangioma's volume.